Novogene Co. Ltd.
Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 12S/18S/IT… Read more
Novogene Co. Ltd. (688315) - Net Assets
Latest net assets as of September 2025: CN¥2.62 Billion CNY
Based on the latest financial reports, Novogene Co. Ltd. (688315) has net assets worth CN¥2.62 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.71 Billion) and total liabilities (CN¥1.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.62 Billion |
| % of Total Assets | 70.71% |
| Annual Growth Rate | 58.17% |
| 5-Year Change | 124.21% |
| 10-Year Change | N/A |
| Growth Volatility | 578.97 |
Novogene Co. Ltd. - Net Assets Trend (2015–2024)
This chart illustrates how Novogene Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Novogene Co. Ltd. (2015–2024)
The table below shows the annual net assets of Novogene Co. Ltd. from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.51 Billion | +1.59% |
| 2023-12-31 | CN¥2.47 Billion | +25.21% |
| 2022-12-31 | CN¥1.98 Billion | +9.91% |
| 2021-12-31 | CN¥1.80 Billion | +60.37% |
| 2020-12-31 | CN¥1.12 Billion | +3.12% |
| 2019-12-31 | CN¥1.09 Billion | +11.81% |
| 2018-12-31 | CN¥972.14 Million | +12.43% |
| 2017-12-31 | CN¥864.65 Million | +8.97% |
| 2016-12-31 | CN¥793.47 Million | +1858.16% |
| 2015-12-31 | CN¥40.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Novogene Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6903.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥966.10 Million | 38.80% |
| Common Stock | CN¥416.20 Million | 16.72% |
| Other Components | CN¥1.11 Billion | 44.48% |
| Total Equity | CN¥2.49 Billion | 100.00% |
Novogene Co. Ltd. Competitors by Market Cap
The table below lists competitors of Novogene Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhongjin Irradiation Incorporated Company
SHE:300962
|
$259.61 Million |
|
TAG Colonia-Immobilien AG
HM:KBU
|
$259.67 Million |
|
PT Raharja Energi Cepu Tbk
JK:RATU
|
$259.72 Million |
|
XINTE ENERGY CO. CL.H YC1
F:9M7
|
$259.79 Million |
|
Cosmo Chem
KO:005420
|
$259.43 Million |
|
SNTEnergy Co Ltd
KO:100840
|
$259.40 Million |
|
Perspective Therapeutics Inc.
NYSE MKT:CATX
|
$259.26 Million |
|
Hubei Yingtong Telecommunication Cable Co Ltd
SHE:002861
|
$259.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Novogene Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,457,457,998 to 2,489,835,892, a change of 32,377,894 (1.3%).
- Net income of 196,788,496 contributed positively to equity growth.
- Dividend payments of 19,396,470 reduced retained earnings.
- Share repurchases of 144,163,366 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥196.79 Million | +7.9% |
| Dividends Paid | CN¥19.40 Million | -0.78% |
| Share Repurchases | CN¥144.16 Million | -5.79% |
| Other Changes | CN¥-850.77K | -0.03% |
| Total Change | CN¥- | 1.32% |
Book Value vs Market Value Analysis
This analysis compares Novogene Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 141.33x to 2.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | CN¥0.10 | CN¥14.31 | x |
| 2016-12-31 | CN¥2.07 | CN¥14.31 | x |
| 2017-12-31 | CN¥2.36 | CN¥14.31 | x |
| 2018-12-31 | CN¥2.69 | CN¥14.31 | x |
| 2019-12-31 | CN¥2.71 | CN¥14.31 | x |
| 2020-12-31 | CN¥2.79 | CN¥14.31 | x |
| 2021-12-31 | CN¥4.48 | CN¥14.31 | x |
| 2022-12-31 | CN¥4.91 | CN¥14.31 | x |
| 2023-12-31 | CN¥6.07 | CN¥14.31 | x |
| 2024-12-31 | CN¥6.07 | CN¥14.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Novogene Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.90%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.32%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.46x
- Recent ROE (7.90%) is below the historical average (13.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 61.17% | 8.00% | 0.65x | 11.85x | CN¥20.74 Million |
| 2016 | 4.94% | 8.54% | 0.37x | 1.55x | CN¥-40.12 Million |
| 2017 | 9.33% | 10.89% | 0.55x | 1.57x | CN¥-5.80 Million |
| 2018 | 10.03% | 9.22% | 0.72x | 1.52x | CN¥326.77K |
| 2019 | 10.56% | 7.45% | 0.78x | 1.82x | CN¥6.03 Million |
| 2020 | 3.27% | 2.45% | 0.74x | 1.81x | CN¥-75.09 Million |
| 2021 | 12.57% | 12.07% | 0.65x | 1.60x | CN¥46.02 Million |
| 2022 | 9.02% | 9.20% | 0.63x | 1.55x | CN¥-19.26 Million |
| 2023 | 7.25% | 8.89% | 0.56x | 1.46x | CN¥-67.69 Million |
| 2024 | 7.90% | 9.32% | 0.58x | 1.46x | CN¥-52.20 Million |
Industry Comparison
This section compares Novogene Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Novogene Co. Ltd. (688315) | CN¥2.62 Billion | 61.17% | 0.41x | $259.49 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |